Health Technology Assessment in Action

Published by: Kowsar

Safety and Efficacy of Mesotherapy in the Treatment of Androgenetic Alopecia: A Systematic Review

Sima Marzban 1 , Bahman Amani 2 and Asra Asgharzadeh 3 , *
Authors Information
1 School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
3 School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, IR Iran
Article information
  • Health Technology Assessment in Action: October 2017, 1 (2); e14078
  • Published Online: April 30, 2017
  • Article Type: Review Article
  • Received: January 23, 2018
  • Revised: March 20, 2018
  • Accepted: March 25, 2017
  • DOI: 10.5812/htaa.14078

To Cite: Marzban S, Amani B, Asgharzadeh A. Safety and Efficacy of Mesotherapy in the Treatment of Androgenetic Alopecia: A Systematic Review, Health Tech Asmnt Act. 2017 ; 1(2):e14078. doi: 10.5812/htaa.14078.

Abstract
Copyright © 2017, Health Technology Assessment in Action. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
Footnotes
References
  • 1. Salman KE, Altunay IK, Kucukunal NA, Cerman AA. Frequency, severity and related factors of androgenetic alopecia in dermatology outpatient clinic: hospital-based cross-sectional study in Turkey. An Bras Dermatol. 2017;92(1):35-40. doi: 10.1590/abd1806-4841.20175241. [PubMed: 28225954]. [PubMed Central: PMC5312176].
  • 2. Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005;10(3):184-9. doi: 10.1111/j.1087-0024.2005.10102.x. [PubMed: 16382660].
  • 3. Paik JH, Yoon JB, Sim WY, Kim BS, Kim NI. The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol. 2001;145(1):95-9. [PubMed: 11453914].
  • 4. Severi G, Sinclair R, Hopper JL, English DR, McCredie MR, Boyle P, et al. Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors. Br J Dermatol. 2003;149(6):1207-13. [PubMed: 14674898].
  • 5. Tahir K, Aman S, Nadeem M, Kazmi AH. Quality of life in patients with androgenetic alopecia. Ann King Edward Med Univ. 2013;19(2):150.
  • 6. Piraccini BM, Alessandrini A. Androgenetic alopecia. Giornaleitaliano di dermatologia evenereologia: organoufficiale, Societaitaliana di dermatologia e sifilografia. 2014;149(1):15-24.
  • 7. Han SH, Byun JW, Lee WS, Kang H, Kye YC, Kim KH, et al. Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. Ann Dermatol. 2012;24(3):311-8. doi: 10.5021/ad.2012.24.3.311. [PubMed: 22879715]. [PubMed Central: PMC3412240].
  • 8. Zhang M, Zhang N. Quality of life assessment in patients with alopecia areata and androgenetic alopecia in the People's Republic of China. Patient Prefer Adherence. 2017;11:151-5. doi: 10.2147/PPA.S121218. [PubMed: 28203058]. [PubMed Central: PMC5293494].
  • 9. Lee WS, Lee HJ, Choi GS, Cheong WK, Chow SK, Gabriel MT, et al. Guidelines for management of androgenetic alopecia based on BASP classification--the Asian Consensus Committee guideline. J Eur Acad Dermatol Venereol. 2013;27(8):1026-34. doi: 10.1111/jdv.12034. [PubMed: 23176122].
  • 10. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-85. [PubMed: 12196747].
  • 11. Kawashima M, Hayashi N, Igarashi A, Kitahara H, Maeguchi M, Mizuno A, et al. Finasteride in the treatment of Japanese men with male pattern hair loss. Eur J Dermatol. 2004;14(4):247-54. [PubMed: 15319158].
  • 12. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-53. doi: 10.1016/j.jaad.2003.06.014. [PubMed: 15034503].
  • 13. Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. J Am Acad Dermatol. 2006;55(1):71-4. doi: 10.1016/j.jaad.2005.07.001. [PubMed: 16781295].
  • 14. Rossi A, Cantisani C, Scarno M, Trucchia A, Fortuna MC, Calvieri S. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther. 2011;24(4):455-61. doi: 10.1111/j.1529-8019.2011.01441.x. [PubMed: 21910805].
  • 15. Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia. J Dermatol. 2012;39(1):27-32. doi: 10.1111/j.1346-8138.2011.01378.x. [PubMed: 21980923].
  • 16. Yoshitake T, Takeda A, Ohki K, Inoue Y, Yamawaki T, Otsuka S, et al. Five-year efficacy of finasteride in 801 Japanese men with androgenetic alopecia. J Dermatol. 2015;42(7):735-8. doi: 10.1111/1346-8138.12890. [PubMed: 25903108].
  • 17. Kanti V, Hillmann K, Kottner J, Stroux A, Canfield D, Blume-Peytavi U. Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial. J Eur Acad Dermatol Venereol. 2016;30(7):1183-9. doi: 10.1111/jdv.13324. [PubMed: 26387973].
  • 18. Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22. doi: 10.1111/jdv.14624. [PubMed: 29178529].
  • 19. Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016;82(2):128-34. doi: 10.4103/0378-6323.177432. [PubMed: 26924401].
  • 20. Mysore V. Mesotherapy in Management of Hairloss - Is it of Any Use? Int J Trichology. 2010;2(1):45-6. doi: 10.4103/0974-7753.66914. [PubMed: 21188025]. [PubMed Central: PMC3002412].
  • 21. Konda D, Thappa DM. Mesotherapy: What is new? Indian J Dermatol Venereol Leprol. 2013;79(1):127-34. doi: 10.4103/0378-6323.104689. [PubMed: 23254749].
  • 22. Gokdemir G. Mesotherapy and platelet-rich plasma for the treatment of hair loss. Turkderm. 2014;48:74.
  • 23. Sobhy N, Aly H, El Shafee A, El Deeb M. Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males. Our Dermatol Online. 2013;4(1):40-5. doi: 10.7241/ourd.20131.08.
  • 24. Azam MH, Morsi HM. Comparative study between 2% minoxidil topical spray vs. intradermal injection (mesotherapy) for treatment of androgenetic alopecia in female patients: a controlled, 4-month randomized Trial. Egypt Dermatol Online J. 2010;6(2):5.
  • 25. Abdallah M, El-Zawahry K, Besar H. Mesotherapy using dutasteride-containing solution in male pattern hair loss: a controlled pilot study. PALD. 2009;20:137-45.
  • 26. Moftah N, Moftah N, Abd-Elaziz G, Ahmed N, Hamed Y, Ghannam B, et al. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol. 2013;27(6):686-93. doi: 10.1111/j.1468-3083.2012.04535.x. [PubMed: 22486925].
  • 27. Ashutosh Talwar NP, Sushma T. A study on the efficacy of mesotherapy withfinasteride versus oral finasteride for the treatment of androgenetic alopecia. Sch J App Med Sci. 2017;5(3):1147-50.
  • 28. Ozdogan S. Hair mesotherapy in treatment of alopecia. J Clin Analyt Med. 2011;2(31):5-8.
  • 29. Duque-Estrada B, Vincenzi C, Misciali C, Tosti A. Alopecia secondary to mesotherapy. J Am Acad Dermatol. 2009;61(4):707-9. doi: 10.1016/j.jaad.2008.11.896. [PubMed: 19577328].
  • 30. El-Komy M, Hassan A, Tawdy A, Solimon M, Hady MA. Hair loss at injection sites of mesotherapy for alopecia. J Cosmet Dermatol. 2017;16(4):e28-30. doi: 10.1111/jocd.12320. [PubMed: 28160387].
  • 31. Kadry R, Hamadah I, Al-Issa A, Field L, Alrabiah F. Multifocal scalp abscess with subcutaneous fat necrosis and scarring alopecia as a complication of scalp mesotherapy. J Drugs Dermatol. 2008;7(1):72-3. [PubMed: 18246702].
  • 32. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141 e5. doi: 10.1016/j.jaad.2017.02.054. [PubMed: 28396101].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments